Plant Name: Angelica sinensis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; ADORA2A; ADORA1; FFAR4; HCAR2; FFAR1; | |
| TSHR; OPRK1; | |
| GABBR1; | |
| PTPN1; | |
| BLM; GLA; FAAH; RECQL; TDP1; ADK; TERT; HPGD; ALDH1A1; AKR1B1; GFER; HSD17B10; ALOX15; AKR1B10; | |
| GAA; ACHE; | |
| HDAC3; | |
| TRPA1; | |
| GABRR1; | |
| ATM; MAPK1; | |
| CA2; CA12; CA1; CA9; CA3; CA14; CA5B; CA5A; CA4; CA6; CA7; | |
| PPARA; PPARD; PPARG; | |
| NR1I2; | |
| DHFR; PTGS1; XDH; | |
| CASP1; CASP7; | |
| MMP9; MMP1; MMP2; | |
| TLR2; | |
| STAT6; TP53; NFKB1; HIF1A; | |
| KMT2A; | |
| SLC28A3; SLC22A8; SLC6A1; SLC22A6; SLC28A2; SLC6A11; SLC28A1; | |
| NPC1; HTT; RAB9A; LMNA; FABP3; GLI1; FABP5; FABP2; FABP4; MAPT; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 2 | CYP2A13 | Cytochrome P450 2A13 | Q16696 | CHEMBL3542436 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| GABA-A receptor | GABRR1 | GABA receptor rho-1 subunit | P24046 | CHEMBL3561 |
| Histone deacetylase | HDAC3 | Histone deacetylase 3 | O15379 | CHEMBL1829 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
| Oxidoreductase | DHFR | Dihydrofolate reductase | P00374 | CHEMBL202 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | OPRK1 | Kappa opioid receptor | P41145 | CHEMBL237 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| Protein Kinase | ATM | Serine-protein kinase ATM | Q13315 | CHEMBL3797 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| SLC superfamily of solute carriers | SLC22A8 | Solute carrier family 22 member 8 | Q8TCC7 | CHEMBL1641348 |
| SLC superfamily of solute carriers | SLC6A1 | GABA transporter 1 | P30531 | CHEMBL1903 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| SLC superfamily of solute carriers | SLC6A11 | GABA transporter 3 | P48066 | CHEMBL5208 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family C GPCR) | GABBR1 | GABA-B receptor 1 | Q9UBS5 | CHEMBL2064 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | GLI1 | Zinc finger protein GLI1 | P08151 | CHEMBL5461 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 5.899E-12 | 7.556E-09 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP3A4, NR1I2 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 9.297E-12 | 1.066E-08 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 4.286E-11 | 3.889E-08 | BLM, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, KMT2A, MMP1, MMP2, MMP9, NR1I2, PPARA, PPARD, PPARG, PTPN1, TP53 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 7.941E-09 | 4.021E-06 | CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.258E-08 | 5.955E-06 | AKR1B1, AKR1B10, CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, NPC1, NR1I2, PPARD |
| BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 2.493E-08 | 1.018E-05 | ADORA2A, AKR1B1, CA3, HPGD, MAPK1, NFKB1, OPRK1, SLC22A8, SLC6A1, STAT6, TLR2, TP53, TRPA1 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.992E-08 | 1.123E-05 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.906E-08 | 1.350E-05 | ALOX15, CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, XDH |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 4.155E-08 | 1.392E-05 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4, NR1I2, PTGS1 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.625E-08 | 1.503E-05 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.026E-07 | 2.903E-05 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, PTGS1 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.764E-07 | 4.685E-05 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.398E-07 | 8.130E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 7.377E-07 | 1.572E-04 | ADORA2A, ATM, CA2, CA7, HCAR2, HIF1A, HTT, MAPK1, NPC1 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 8.039E-07 | 1.683E-04 | ADORA1, ADORA2A, FFAR4, NFKB1, PPARA, PPARD, PPARG |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 8.339E-07 | 1.713E-04 | CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.252E-06 | 2.500E-04 | ADORA1, ADORA2A, ATM, CA2, CA7, HCAR2, HIF1A, HTT, MAPK1, NPC1, OPRK1, TRPA1 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.791E-06 | 3.451E-04 | ACHE, ADORA2A, BLM, CASP1, GLA, HPGD, HTT, KMT2A, MAPK1, MAPT, MMP9, NFKB1, PPARG, RAB9A, SLC22A6, SMN1, SMN2, STAT6, TERT, TP53, TRPA1, XDH |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.778E-06 | 3.451E-04 | ADORA1, CA2, CA4, CA9, HPGD, SLC22A6, SLC22A8, TSHR |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 2.520E-06 | 4.650E-04 | HPGD, MMP2, MMP9, TERT |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 2.944E-06 | 5.048E-04 | CYP2A13, CYP2A6, CYP2D6 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 2.944E-06 | 5.048E-04 | ADORA1, ADORA2A, ADORA3 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.040E-06 | 5.172E-04 | CYP1A2, CYP2A13, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 4.313E-06 | 7.009E-04 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 7.021E-06 | 1.062E-03 | BLM, RECQL, TP53 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 7.021E-06 | 1.062E-03 | ADORA1, ADORA2A, ADORA3 |
| MF | GO:0005488; binding | GO:0046983; protein dimerization activity | 8.841E-06 | 1.296E-03 | ACHE, ADORA1, ADORA2A, ATM, BLM, GLA, HIF1A, HPGD, KMT2A, MAPT, NFKB1, PPARD, PPARG, SLC22A6, TERT, TLR2, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 9.993E-06 | 1.414E-03 | ACHE, ADORA2A, CASP1, FFAR1, HCAR2, HIF1A, PPARD, TLR2 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 9.997E-06 | 1.414E-03 | CYP1A2, CYP2C19, CYP2C9 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 1.082E-05 | 1.491E-03 | ADORA1, ADORA2A, ADORA3, FFAR1, FFAR4, GABBR1, GABRR1, NPC1, OPRK1, SLC22A6, SLC22A8, SLC28A1, SLC28A2, SLC28A3, SLC6A1, SLC6A11, TLR2, TRPA1, TSHR |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 1.345E-05 | 1.807E-03 | ADORA1, ADORA2A, ADORA3, ATM, FABP3, KMT2A, LMNA, PPARD, PPARG, TERT, TLR2, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0090399; replicative senescence | 1.821E-05 | 2.319E-03 | ATM, TERT, TP53 |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 1.959E-05 | 2.397E-03 | SLC28A2, SLC28A3 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 1.959E-05 | 2.397E-03 | SLC28A1, SLC28A3 |
| MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 1.959E-05 | 2.397E-03 | CYP2A13, CYP2A6 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 1.959E-05 | 2.397E-03 | SLC28A2, SLC28A3 |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 2.360E-05 | 2.763E-03 | ADORA2A, CA2, CA7 |
| BP | GO:0009987; cellular process | GO:1902533; positive regulation of intracellular signal transduction | 2.495E-05 | 2.874E-03 | ADORA1, AKR1B1, ALOX15, ATM, CASP1, FFAR4, HDAC3, HTT, MAPK1, OPRK1, PPARD, PTPN1, TLR2, TP53, XDH |
| BP | GO:0007610; behavior | GO:0007612; learning | 3.231E-05 | 3.530E-03 | HIF1A, HTT, KMT2A, OPRK1, SLC6A1, TLR2 |
| BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 3.242E-05 | 3.530E-03 | CASP1, CASP7, MAPT, PPARG, XDH |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 4.340E-05 | 4.588E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
| CC | GO:0044464; cell part | GO:0030673; axolemma | 4.576E-05 | 4.791E-03 | ADORA1, ADORA2A, MAPT |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 5.861E-05 | 5.726E-03 | SLC28A1, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 5.861E-05 | 5.726E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 5.861E-05 | 5.726E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 5.861E-05 | 5.726E-03 | SLC28A1, SLC28A3 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 5.861E-05 | 5.726E-03 | ADORA1, ADORA2A |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 6.547E-05 | 6.251E-03 | AKR1B1, BLM, CASP7, MAPK1, MMP2, NFKB1, PPARG, TP53, TSHR |
| BP | GO:0008152; metabolic process | GO:0051000; positive regulation of nitric-oxide synthase activity | 6.625E-05 | 6.251E-03 | DHFR, HIF1A, TERT |
| BP | GO:0050896; response to stimulus | GO:0031000; response to caffeine | 6.625E-05 | 6.251E-03 | ADORA2A, PPARG, TP53 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 6.660E-05 | 6.251E-03 | NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 7.074E-05 | 6.611E-03 | AKR1B1, CA12, CA2, CA7, FABP3, FABP4, FFAR1, HIF1A, HTT, MAPK1, NPC1, PPARG, TP53, TRPA1 |
| BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 7.632E-05 | 7.102E-03 | ADORA1, ADORA2A, PPARA, PPARG, TP53 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.012E-04 | 9.221E-03 | HIF1A, LMNA, PPARD, TERT, TP53 |
| BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 1.082E-04 | 9.657E-03 | DHFR, GLA, HIF1A, MAPT, TP53, XDH |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 9.436E-24 | 2.055E-19 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.853E-18 | 3.126E-14 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, DHFR |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.780E-17 | 2.602E-13 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 5.796E-23 | 9.912E-21 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 5.661E-10 | 4.840E-08 | FABP2; FABP3; FABP4; FABP5; MMP1; PPARG; PPARA; PPARD |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.894E-07 | 8.096E-06 | HCAR2; GABBR1; ADORA2A; ADORA1; MAPK1; PPARA; GLI1; NFKB1; TSHR |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.431E-07 | 8.096E-06 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 5.111E-07 | 1.748E-05 | CYP2C9; CYP2A6; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 7.160E-07 | 1.853E-05 | CYP2C9; CYP2A6; CYP2A13; CYP2D6; CYP1A2; CYP3A4 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 7.844E-06 | 1.159E-04 | MMP1; MMP2; MAPK1; PPARG; GLI1; HIF1A; TP53; MMP9; NFKB1; PPARD |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 8.671E-07 | 1.853E-05 | MMP1; MMP2; MAPK1; MMP9; TP53 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.428E-06 | 2.713E-05 | CYP2C9; CYP2A6; CYP2A13; CYP1A2; CYP3A4; CYP2C19 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 8.803E-06 | 1.159E-04 | CYP2C9; CYP2D6; ALOX15; MAPK1; CYP2C19; PTGS1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 3.137E-05 | 3.576E-04 | CASP7; LMNA; MAPK1; ATM; TP53; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 8.814E-06 | 1.159E-04 | CYP2C9; CYP2A6; CYP1A2; ALDH1A1; CYP3A4 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.257E-05 | 1.535E-04 | HPGD; KMT2A; ATM; PPARG; TP53; MMP9; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 3.971E-05 | 4.244E-04 | MAPK1; STAT6; TP53; MMP9; NFKB1; TLR2 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 8.018E-06 | 1.159E-04 | AKR1B10; GAA; AKR1B1; GLA |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.377E-04 | 1.808E-03 | GAA; ALOX15; ADK; AKR1B1; CYP2C19; CYP3A4; HSD17B10; PTGS1; DHFR; CYP2C9; CYP2A6; AKR1B10; CYP1A2; ALDH1A1; XDH |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.916E-04 | 1.560E-03 | GABBR1; GABRR1; ADORA2A; ADORA3; ADORA1; OPRK1; TSHR |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.432E-04 | 1.808E-03 | MMP2; MAPK1; TP53; HIF1A; MMP9; TLR2 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 9.869E-05 | 9.375E-04 | FABP4; ADORA1; TSHR; PTGS1 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 9.194E-05 | 9.248E-04 | CASP7; CASP1; NFKB1; TLR2 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.690E-04 | 1.445E-03 | ADORA3; ADORA1; MAPK1; TP53; NFKB1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.470E-04 | 1.323E-03 | CYP2C9; ALOX15; CYP2C19; PTGS1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 8.791E-04 | 5.568E-03 | GABBR1; MMP2; MAPK1; MMP9 |
| hsa04727 | GABAergic synapse_Homo sapiens_hsa04727 | 5.644E-04 | 3.712E-03 | GABBR1; GABRR1; SLC6A11; SLC6A1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 3.069E-04 | 2.099E-03 | CASP7; CASP1; MAPK1; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.301E-03 | 7.670E-03 | CASP7; MAPK1; MMP9; NFKB1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.685E-03 | 9.603E-03 | HDAC3; MAPK1; TP53; HIF1A |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.605E-03 | 1.310E-02 | MAPK1; PPARA; TP53; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 2.823E-03 | 1.335E-02 | RAB9A; TP53; NFKB1; TLR2 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.900E-03 | 1.015E-02 | MAPK1; NFKB1; PPARD |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 5.979E-03 | 2.361E-02 | CASP7; MAPK1; MAPT; HSD17B10 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.889E-03 | 1.335E-02 | MAPK1; TP53; NFKB1 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 2.098E-03 | 1.087E-02 | AKR1B10; AKR1B1; GLA |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.900E-03 | 1.015E-02 | CASP1; MAPK1; NFKB1 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 2.767E-03 | 1.335E-02 | STAT6; NFKB1; TLR2 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 3.843E-03 | 1.603E-02 | MAPK1; TP53; NFKB1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 2.587E-04 | 1.843E-03 | MAPK1; PPARG; TP53 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 3.016E-03 | 1.357E-02 | MAPK1; TP53; HIF1A |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 9.144E-03 | 3.168E-02 | MAPK1; ATM; TP53; MMP9; NFKB1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.020E-03 | 6.227E-03 | CYP2A6; CYP3A4; XDH |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 6.681E-03 | 2.539E-02 | MAPK1; TP53; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 9.449E-03 | 3.168E-02 | MMP2; MAPK1; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 3.843E-03 | 1.603E-02 | MAPK1; NFKB1; TLR2 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 7.765E-03 | 2.825E-02 | PPARG; TP53; NFKB1 |
| hsa05032 | Morphine addiction_Homo sapiens_hsa05032 | 7.103E-03 | 2.640E-02 | GABBR1; GABRR1; ADORA1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 3.554E-03 | 1.558E-02 | CA2; SLC22A8; CYP3A4 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.184E-02 | 3.553E-02 | HDAC3; MAPK1; TP53; NFKB1 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 9.449E-03 | 3.168E-02 | FAAH; GABRR1; MAPK1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 6.076E-03 | 2.361E-02 | CASP1; MAPK1; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 9.967E-03 | 3.277E-02 | MAPK1; HIF1A; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.077E-02 | 3.349E-02 | MAPK1; NFKB1; TLR2 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.023E-02 | 3.301E-02 | MAPK1; NFKB1; TLR2 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.162E-02 | 3.547E-02 | PTPN1; PPARA; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.437E-02 | 4.236E-02 | MAPK1; NFKB1; TLR2 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.503E-02 | 4.355E-02 | MAPK1; TP53; NFKB1 |
| hsa04142 | Lysosome_Homo sapiens_hsa04142 | 1.604E-02 | 4.572E-02 | NPC1; GAA; GLA |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 7.629E-07 | 1.853E-05 | CYP2A6; CYP1A2; XDH |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 8.337E-03 | 2.970E-02 | AKR1B10; AKR1B1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.047E-02 | 3.316E-02 | AKR1B10; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 4.360E-03 | 1.775E-02 | CA2; CA4 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2; TERT |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2; TERT |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1; TP53; MMP9 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | OPRK1 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1; MMP2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH; HCAR2 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; CYP2D6 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; SLC6A1 |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1; ADK |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | OPRK1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2; TERT; MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Fabry's disease | E75.2 | GLA |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | OPRK1; ACHE; MAPT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| N00-N99: Diseases of the genitourinary system | Urinary tract infections | N39.0 | DHFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | ATM |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; OPRK1; PPARD; PPARD; PPARG |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS1; FAAH |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; OPRK1; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| C00-D49: Neoplasms | Myeloma | C90 | SLC6A1 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; HIF1A |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1 |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; MMP2 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRK1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1; ACHE; MAPT |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS1; ADORA2A; OPRK1; ADK; FAAH; TRPA1; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ADORA2A; ADORA1; ACHE |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1; AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Opiate dependence | F11 | OPRK1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; TLR2 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1; MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; PPARD; HCAR2 |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA2A; ADORA1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | ADORA3; TP53; CA1; CA9; MAPK1; MMP9; NFKB1; TLR2; MMP2; HIF1A; ACHE; DHFR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HCAR2 |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; ADORA2A; ADORA1; CA1; CA1; AKR1B1; ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; XDH; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| A00-B99: Certain infectious and parasitic diseases | Pulmonary and extrapulmonary tuberculosis | A15-A19 | DHFR |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | OPRK1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | DHFR |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE; MAPT; PPARG; PPARG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; TERT |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1; TERT |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; NFKB1; PPARD; FFAR1; HCAR2; PPARG; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1; ADORA2A; ADORA1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TP53; CA9; MAPK1; MMP9; TLR2; MMP2; HIF1A; DHFR |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | OPRK1 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; MMP9 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; FAAH; ACHE |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD; NR1I2; HCAR2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1; MMP1; AKR1B1; DHFR |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; ADORA1; AKR1B1; FFAR1; PPARG |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| NA: NA | Rheumatold arthritis | NA | PTGS1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; TERT |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; HCAR2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1 |